Conflict of interest statement
Masatoshi Kudo received lecture fees from Bayer, Eisai, MSD, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, AbbVie, Medico's Hirata, Astellas Pharma, and Bristol-Myers Squibb, and advisory consulting fees from Kowa, MSD, Bristol-Myers Squibb, Bayer, Chugai, Taiho, Eisai, and Ono Pharmaceutical.
Lenvatinib as an Initial Treatment in Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept StudyM Kudo et al. Cancers (Basel) 11 (8). PMID 31370183.Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous di …
Efficacy of Combination Therapy With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Intermediate-Stage Hepatocellular CarcinomaK Endo et al. Scand J Gastroenterol 53 (12), 1575-1583. PMID 30577723.The addition of RFA to TACE improved cumulative overall and recurrence-free survival in patients with intermediate-stage HCC, especially in patients with AFP <100.
Recent Advances in Medical Management of Hepatocellular CarcinomaK Ikeda. Hepatol Res 49 (1), 14-32. PMID 30308081. - ReviewTranscatheter arterial therapies for hepatocellular carcinoma (HCC) have developed during the last decade. A fine powder formulation of cisplatin and the new platinum age …
Intermediate Hepatocellular Carcinoma: Current Treatments and Future PerspectivesJF Dufour et al. Ann Oncol 24 Suppl 2, ii24-9. PMID 23715940. - ReviewCurrent guidelines recommend transarterial chemoembolization (TACE) as the standard treatment of Barcelona-Clinic Liver Cancer (BCLC)-B patients. However, the long-term s …
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma (TRACE): Study Protocol for a Randomized Controlled TrialBA Seinstra et al. Trials 13, 144. PMID 22913492. - Randomized Controlled TrialIn this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group …